Apellis Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $40.86
- Today's High:
- $42.71
- Open Price:
- $41.2
- 52W Low:
- $33.32
- 52W High:
- $70.755
- Prev. Close:
- $41.51
- Volume:
- 1327933
Company Statistics
- Market Cap.:
- $7.12 billion
- Book Value:
- 1.534
- Revenue TTM:
- $75.42 million
- Operating Margin TTM:
- -788.38%
- Gross Profit TTM:
- $69.79 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.27%
- Return on Equity TTM:
- -353.93%
Company Profile
Apellis Pharmaceuticals Inc had its IPO on 2017-11-09 under the ticker symbol APLS.
The company operates in the Healthcare sector and Biotechnology industry. Apellis Pharmaceuticals Inc has a staff strength of 767 employees.
Stock update
Shares of Apellis Pharmaceuticals Inc opened at $41.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $40.86 - $42.71, and closed at $42.24.
This is a +1.76% increase from the previous day's closing price.
A total volume of 1,327,933 shares were traded at the close of the day’s session.
In the last one week, shares of Apellis Pharmaceuticals Inc have slipped by -2.85%.
Apellis Pharmaceuticals Inc's Key Ratios
Apellis Pharmaceuticals Inc has a market cap of $7.12 billion, indicating a price to book ratio of 17.6717 and a price to sales ratio of 51.2635.
In the last 12-months Apellis Pharmaceuticals Inc’s revenue was $75.42 million with a gross profit of $69.79 million and an EBITDA of $-593060992. The EBITDA ratio measures Apellis Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Apellis Pharmaceuticals Inc’s operating margin was -788.38% while its return on assets stood at -45.27% with a return of equity of -353.93%.
In Q4, Apellis Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 62.4%.
Apellis Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-6.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Apellis Pharmaceuticals Inc’s profitability.
Apellis Pharmaceuticals Inc stock is trading at a EV to sales ratio of 42.7903 and a EV to EBITDA ratio of -8.0318. Its price to sales ratio in the trailing 12-months stood at 51.2635.
Apellis Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $760.22 million
- Total Liabilities
- $167.61 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $851000
- Dividend Payout Ratio
- 0%
Apellis Pharmaceuticals Inc ended 2024 with $760.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $760.22 million while shareholder equity stood at $169.87 million.
Apellis Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $167.61 million in other current liabilities, 11000.00 in common stock, $-2308860000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $551.80 million and cash and short-term investments were $551.80 million. The company’s total short-term debt was $5,625,000 while long-term debt stood at $92.74 million.
Apellis Pharmaceuticals Inc’s total current assets stands at $719.52 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $7.73 million compared to accounts payable of $37.34 million and inventory worth $85.71 million.
In 2024, Apellis Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $851000.
Comparatively, Apellis Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $42.24
- 52-Week High
- $70.755
- 52-Week Low
- $33.32
- Analyst Target Price
- $85.67
Apellis Pharmaceuticals Inc stock is currently trading at $42.24 per share. It touched a 52-week high of $70.755 and a 52-week low of $70.755. Analysts tracking the stock have a 12-month average target price of $85.67.
Its 50-day moving average was $43.99 and 200-day moving average was $62.23 The short ratio stood at 7.4 indicating a short percent outstanding of 0%.
Around 1494.4% of the company’s stock are held by insiders while 8975.8% are held by institutions.
Frequently Asked Questions About Apellis Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.